JPWO2024048489A5 - - Google Patents

Info

Publication number
JPWO2024048489A5
JPWO2024048489A5 JP2024544226A JP2024544226A JPWO2024048489A5 JP WO2024048489 A5 JPWO2024048489 A5 JP WO2024048489A5 JP 2024544226 A JP2024544226 A JP 2024544226A JP 2024544226 A JP2024544226 A JP 2024544226A JP WO2024048489 A5 JPWO2024048489 A5 JP WO2024048489A5
Authority
JP
Japan
Prior art keywords
gene
agent
cers1
bakuchiol
dimethylocta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544226A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024048489A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2023/030871 external-priority patent/WO2024048489A1/ja
Publication of JPWO2024048489A1 publication Critical patent/JPWO2024048489A1/ja
Publication of JPWO2024048489A5 publication Critical patent/JPWO2024048489A5/ja
Pending legal-status Critical Current

Links

JP2024544226A 2022-08-29 2023-08-28 Pending JPWO2024048489A1 (https=)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022136384 2022-08-29
JP2023049423 2023-03-27
PCT/JP2023/030871 WO2024048489A1 (ja) 2022-08-29 2023-08-28 レチノール様作用の誘導に用いるための剤およびその用途

Publications (2)

Publication Number Publication Date
JPWO2024048489A1 JPWO2024048489A1 (https=) 2024-03-07
JPWO2024048489A5 true JPWO2024048489A5 (https=) 2025-12-24

Family

ID=90099881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544226A Pending JPWO2024048489A1 (https=) 2022-08-29 2023-08-28

Country Status (3)

Country Link
JP (1) JPWO2024048489A1 (https=)
CN (1) CN119730842A (https=)
WO (1) WO2024048489A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859021B2 (en) * 2007-05-14 2014-10-14 Sytheon Skin appearance through gene manipulation
KR102142464B1 (ko) * 2020-02-18 2020-08-10 (주)아모레퍼시픽 바쿠치올을 포함하는 피부 장벽 강화 또는 보습용 조성물

Similar Documents

Publication Publication Date Title
Bouyahya et al. The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions
Castellano et al. Synthesis and biochemical evaluation of Δ2-isoxazoline derivatives as DNA methyltransferase 1 inhibitors
NO20082768L (no) Levodopa prodroge mesylat, sammensetninger og anvendelser derav
CL2008000329A1 (es) Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, depresion, enfermedad pulmonar, entre otras enfermedades.
CO6430467A2 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosméticas o farmacéuticas
CO6541537A2 (es) Composición para el cuidado personal que proporciona mejora de suavidad y silencio y articulos usnado la misma
ES2330291A1 (es) Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
UA101301C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
CL2012001432A1 (es) Producto de combinacion farmacéutica que comprende bromuro de 4-[hidroxi-(difenil)-metil]-1-{2-[(fenil-metil)-oxi]-etil}-1-azonia-biciclo-[2.2.2]-octano y trifenil-acetato de 4-{(1r)-2-[(6-{2-[(2,6-dicloro-bencil)-oxi]-etoxi}-hexil)-amino]-1-hidroxi-etil}-2-(hidroxi-metil)-fenol; y su uso para tratar enfermedades respiratorias.
CL2012003027A1 (es) Metodo para determinar la posibilidad de respuesta de un individuo con sindrome x fragil (fxs); kit de diagnostico que comprende un agente para medir una transcripcion de arnm de retardo mental x fragil 1 (fmr1), los niveles de proteina de fmr1, o la metilación de una region del gen de fmr1.
Lu Epigenetic modification enzymes: catalytic mechanisms and inhibitors
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
WO2007077257A3 (en) Acne lesions biomarkers and modulators thereof
WO2012007584A3 (en) Composition for the treatment of superficial lesions
JPWO2024048489A5 (https=)
JP2008013542A5 (https=)
Ara et al. Preventive effects of a Kampo medicine, Shosaikoto, on inflammatory responses in LPS-treated human gingival fibroblasts
Cannito et al. From Metabolic to Epigenetic Memory: The Impact of Hyperglycemia-Induced Epigenetic Signature on Kidney Disease Progression and Complications
BRPI0514422A (pt) biotransformação enantioseletiva para o preparo de intermediários do inibidor de proteìna tirosina quinase
JP2024114037A5 (https=)
FR3117340B1 (fr) Utilisation cosmétique, nutraceutique ou dermatologique d’une souche deLactobacillus crispatus et / ou d’une composition la comprenant
SG143203A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
NO20055367L (no) Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst
JP2017508755A (ja) ミネラル成分及びキヌア抽出物を含む皮膚保湿用化粧料組成物
BRPI0817429A8 (pt) processo para a preparação de espumas de mastigar aromatizadas para produtos cosméticos